316 related articles for article (PubMed ID: 25202923)
1. Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.
Radzio J; Hanley K; Mitchell J; Ellis S; Deyounks F; Jenkins L; Heneine W; García-Lerma JG
J Acquir Immune Defic Syndr; 2014 Dec; 67(4):365-9. PubMed ID: 25202923
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures.
Smith JM; Srinivasan P; Teller RS; Lo Y; Dinh CT; Kiser PF; Herold BC
J Acquir Immune Defic Syndr; 2015 Jan; 68(1):1-5. PubMed ID: 25321184
[TBL] [Abstract][Full Text] [Related]
3. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
5. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women.
Tarleton J; Chen BA; Meyn LA; Hendrix CW; Marzinke MA; Achilles SL
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):182-188. PubMed ID: 32568766
[TBL] [Abstract][Full Text] [Related]
7. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
Cong ME; Mitchell J; Sweeney E; Bachman S; Hanson DL; Heneine W; García-Lerma JG
J Infect Dis; 2013 Aug; 208(3):463-7. PubMed ID: 23633402
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
10. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
Nanda K; Callahan R; Taylor D; Wang M; Agot K; Jenkins D; Van Damme L; Dorflinger L;
Contraception; 2016 Jul; 94(1):40-7. PubMed ID: 26972780
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
Anderson PL; Glidden DV; Bushman LR; Heneine W; García-Lerma JG
J Antimicrob Chemother; 2014 Sep; 69(9):2470-6. PubMed ID: 24862094
[TBL] [Abstract][Full Text] [Related]
12. Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques.
Radzio J; Hanley K; Mitchell J; Ellis S; Deyounks F; Jenkins LT; Hanson D; Heneine W; García-Lerma JG
AIDS; 2014 Jun; 28(10):1431-9. PubMed ID: 24759208
[TBL] [Abstract][Full Text] [Related]
13. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
[TBL] [Abstract][Full Text] [Related]
15. Repeated administration of high-dose depot medroxyprogesterone acetate does not alter SHIV
Srinivasan P; Zhang J; Dinh CT; Teller RS; McNicholl JM; Kiser PF; Herold BC; Smith JM
J Med Primatol; 2017 Aug; 46(4):129-136. PubMed ID: 28748662
[TBL] [Abstract][Full Text] [Related]
16. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.
García-Lerma JG; Otten RA; Qari SH; Jackson E; Cong ME; Masciotra S; Luo W; Kim C; Adams DR; Monsour M; Lipscomb J; Johnson JA; Delinsky D; Schinazi RF; Janssen R; Folks TM; Heneine W
PLoS Med; 2008 Feb; 5(2):e28. PubMed ID: 18254653
[TBL] [Abstract][Full Text] [Related]
17. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
[TBL] [Abstract][Full Text] [Related]
19. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Plosker GL
Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
[TBL] [Abstract][Full Text] [Related]
20. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
